Research chemicalStimulantSympathomimetic amineDMAA analog

DMBA (AMP Citrate)

Also known as AMP Citrate · 1,3-dimethylbutylamine · 4-amino-2-methylpentane citrate · Pouchung tea extract

Written by enwyReviewed 5 Aug 20262 sources0 comments

DMBA (1,3-dimethylbutylamine, sold as 'AMP Citrate') is a structural analog of DMAA introduced to supplements as a substitute stimulant. It has essentially no human safety data, and the FDA warned that it does not qualify as a dietary ingredient and poses cardiovascular risks.

01 Overview

1,3-Dimethylbutylamine differs from DMAA by one carbon and was marketed under the misleading name 'AMP Citrate' or as an extract of Pouchung tea. Analytical surveys found it in numerous pre-workout and weight-loss products, none supported by evidence of natural sourcing.

Because DMBA is a close analog of a compound tied to serious cardiovascular harm and has no meaningful safety testing in humans, the FDA issued warning letters in 2015 declaring products containing it adulterated.

02 Mechanism

Presumed indirect sympathomimetic like DMAA, increasing catecholamine signalling and raising heart rate and blood pressure.

03 Dosing

Tier	Dose	Route	Notes
Common	100–300 mg	Oral	Range found in labelled supplements; no established safe dose.

04 Effects

Effect	Magnitude	Evidence
Perceived stimulationUsers report energy and focus, generally weaker than DMAA.	Mild-moderate	Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence	Countermeasures
Anxiety and overstimulationRestlessness and anxiety typical of the stimulant class.	Mild	Common	Anecdotal
Cardiovascular strainRaised heart rate and blood pressure expected from the DMAA-like structure.	Severe	Unquantified	Preclinical

06 Legal status

United States

Illegal dietary ingredient (FDA)

FDA warning letters issued in 2015. · as of Jan 2026

07 References

An amphetamine isomer whose efficacy and safety in humans has never been studied, DMBA, is found in dietary supplementsDrug Testing and Analysis, 2015 (PubMed)

FDA warning letters on DMBAU.S. FDA

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.